Twilio Surges 24% as Q1 Revenue Jumps 20%, AI Voice Ramps
Twilio stock climbed nearly 24% after Q1 2026 revenue grew 20% year-over-year to $1.4 billion, with GAAP profitability surging and full-year guidance raised.
What Is Post-Earnings Drift? Whisper Numbers Explained
Learn why stocks keep moving after earnings reports. Understand whisper numbers, post-earnings drift (PEAD), and how these forces drive market moves every quarter.
Paramount Skydance’s $110B Warner Bros. Bet Nears Closing
WBD shareholders approved Paramount Skydance’s $110B takeover. EU regulators lean yes; FCC weighs foreign ownership stakes in CBS and CNN.
Atlassian Jumps 24% on Q3 Earnings Blowout and AI Momentum
Atlassian stock surged 24% after Q3 FY2026 results crushed estimates — revenue hit $1.79B (+32% YoY), non-GAAP EPS of $1.75 beat by 34%, and Rovo AI credits grew 20%+ monthly.
EPS, Diluted EPS, and Non-GAAP Earnings Explained
Learn how basic EPS, diluted EPS, and non-GAAP adjusted earnings are calculated—and why each number tells a different story during earnings season.
Blackstone’s $10B Credit Fund: How Private Lending Hit $520B
Blackstone’s Capital Opportunities Fund V closed oversubscribed at $10B. Private credit now rivals the entire high-yield bond market—here’s who’s winning and what risks regulators see.
Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge
Merck Q1 2026: $16.3B revenue beat, guidance raised. A $9B acquisition charge drove a GAAP loss, but Winrevair growth signals strong underlying fundamentals.
How Short Selling Works: Short Interest and Squeezes
Short selling lets investors profit from falling prices. Learn how it works, what short interest means, and what triggers a short squeeze.
30-Year Treasury Near 5%: The Forces Keeping U.S. Borrowing Costs High
The 30-year Treasury yield stands at 4.987% on April 30, 2026 — nearly 5% — as term premium surges on sticky inflation, rising supply, and fading foreign demand for US debt.
Eli Lilly Q1 2026: Revenue Surges 56% as GLP-1 Boom Deepens
Eli Lilly beat Q1 2026 estimates with $19.8B revenue (+56%), EPS of $8.26 (+170%), driven by Mounjaro, Zepbound, and newly launched oral pill Foundayo.